首页> Journal of medicinal chemistry> Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.

Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.

导出 LinkOut

翻译打印收藏纠错

第一作者： J Michael,Ellis

第一单位： Department of Discovery Chemistry, ‡Department of Process Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc. , 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States.

作者： J Michael,Ellis ^[1] ; Michael D,Altman ; Alan,Bass ; John W,Butcher ; Alan J,Byford ; Anthony,Donofrio ; Sheila,Galloway ; Andrew M,Haidle ; James,Jewell ; Nancy,Kelly ; Erica K,Leccese ; Sandra,Lee ; Matthew,Maddess ; J Richard,Miller ; Lily Y,Moy ; Ekundayo,Osimboni ; Ryan D,Otte ; M Vijay,Reddy ; Kerrie,Spencer ; Binyuan,Sun ; Stella H,Vincent ; Gwendolyn J,Ward ; Grace H C,Woo ; Chiming,Yang ; Hani,Houshyar ; Alan B,Northrup

作者单位： Department of Discovery Chemistry, ‡Department of Process Research, §Department of Immunology, ∥Department of Pharmacology, ⊥Department of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, #Department of Safety Assessment and Laboratory Animal Resources, and ▽Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc. , 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States. ^[1]